Therapeutic goods administration provisionally approves moderna's omicron-containing bivalent booster candidate, mrna-1273.214, for australia

Australia becomes among the first countries in the world to approve the use of a next-generation bivalent covid-19 vaccine mrna-1273.214, an omicron-containing bivalent vaccine, has demonstrated significantly higher antibody titers against all tested variants, including omicron ba.1 and ba.4/5 subvariants moderna expects to supply mrna-1273.214 to australia in september cambridge, ma / accesswire / august 30, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that the therapeutic goods administration (tga) in australia has granted provisional approval for its omicron-containing bivalent booster vaccine, mrna-1273.214 (spikevax bivalent original/omicron) as a booster dose for active immunization to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. spikevax bivalent original/omicron is a next-generation bivalent vaccine that contains 25 Μg of mrna-1273 (spikevax) and 25 Μg of a vaccine candidate targeting the omicron variant of concern (ba.1).
MRNA Ratings Summary
MRNA Quant Ranking